Meet our portfolio

Catalym

Catalym is a clinical-stage biotech developing visugromab, a humanized monoclonal antibody engineered to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15) which acts as a key regulator of immune resistance to cancer therapies.

Commit Biologics is a pioneer in activating the complement system to kill specific target cells, with applications in cancers and autoimmune diseases. Spun out of Aarhus University, and building on more than three decades of research, Commit’s Bispecific Complement Engaging (BiCE™) platform can supercharge a conventional monoclonal antibody to activate the complement system more effectively.

Best-in-class Immune regulator in Ulcerative Colitis

Targeting Tumor-promoting Macrophages

Targeting Memory T-cells in Autoimmunity

SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies. SynOx is led by an experienced team of industry professionals with a successful track record of developing and bringing products to commercialisation.

Bicara Therapeutics is a clinical-stage biotechnology company developing dual-action biologics designed to modulate the tumor microenvironment to elicit a potent and durable anti-tumor response.

Tridek-One is developing a novel CD31 agonist approach to modulate immune activation for the treatment of autoimmune diseases.

Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.

Enhanc3D Genomics is a functional genomics company that has developed a proprietary disruptive technology to profile three-dimensional genome folding at high resolution.
Understanding DNA organization and long-distance interactions allows to link gene enhancers and non-coding genetic variants to their target genes.
Enhanc3D Genomics has a mission to be a first in class high precision navigator of the non-coding regions of the genome hereby unlocking novel disease-related targets.

Anavo’s mission is to pioneer systematic drug discovery and development approaches aimed at phosphatases, a rich and largely untapped therapeutic target class. Anavo’s approach focuses on combining profound understanding of phosphatase biology with deep drug discovery expertise and state-of-the-art technologies to design first-in- class and best-in-class small molecule modulators of phosphatase activity.

Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapies for the treatment of cancer and viral diseases.